Effects of isoprenaline plus phenylephrine by pressurized aerosol on blood gases, ventilation, and perfusion in chronic obstructive lung disease.
The effects of a combined isoprenaline-phenylephrine inhalant in chronic obstructive lung disease were assessed in 23 patients. Significant changes occurred in blood gas tensions after inhalation, together with an overall improvement in ventilation/perfusion ratios. Cardiac output and physiological shunt were not significantly increased. Hence the addition of phenylephrine probably prevents the increase of hypoxaemia which may result from the disproportionate ventilation/perfusion ratio produced by sympathomimetics or xanthines used alone. The combination aerosol has a satisfactory bronchodilator effect, and is additionally safe if used by a severely hypoxic patient unaware of the seriousness of his condition.
D000328:Adult; D000336:Aerosols; D000368:Aged; D002245:Carbon Dioxide / Q000097:blood*; D002302:Cardiac Output / Q000187:drug effects; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D000860:Hypoxia / Q000188:drug therapy; D007545:Isoproterenol / Q000008:administration & dosage*; D008171:Lung Diseases / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010100:Oxygen / Q000097:blood*; D010656:Phenylephrine / Q000008:administration & dosage*; D010919:Placebos; D013147:Spirometry; D014692:Ventilation-Perfusion Ratio / Q000187:drug effects*
D000336:Aerosols; D010919:Placebos; D002245:Carbon Dioxide; D010656:Phenylephrine; D007545:Isoproterenol; D010100:Oxygen